FLT3 Inhibitor BMF-500

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable, covalent and selective inhibitor of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, FLT3 inhibitor BMF-500 selectively targets and irreversibly binds to a reactive cysteine in the active site of FLT3. This inhibits the activity of FLT3 and prevents FLT3-mediated downstream signaling. This inhibits the proliferation of FLT3-expressing cancer cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias.

**Synonyms:** - BMF 500 - BMF-500 - BMF500